Your session is about to expire
← Back to Search
Pembrolizumab + Entinostat for Lymphoma
Study Summary
This trial is testing the effects of two drugs, Pembrolizumab and Entinostat, when used together to treat lymphoma. The goal is to see if the combination is more effective than either drug used alone, and to learn about any potential side effects.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2024 Phase 2 trial • 57 Patients • NCT03004183Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
How many people with the disease are participating in this trial?
"47 individuals that meet the specified prerequisites are required for this clinical trial. Patients have the choice of participating at different locations, such as Memorial Sloan Kettering Basking Ridge in Basking Ridge, New jersey and Memorial Sloan Kettering Commack in Commack, New york."
What other researchers have looked into Pembrolizumab?
"Pembrolizumab was first studied at Johns Hopkins University/Sidney Kimmel Cancer Center in 2009. In total, there have been 279 completed clinical trials on this medication. As of now, 1,013 different medical centres are actively recruiting patients for further study – many of these locations situated in Basking Ridge, New jersey."
Are we still able to sign up for this experiment?
"That is correct, the available information does show that the trial is still looking for patients. According to the posting dates on clinicaltrials.gov, recruitment started on 6/7/2017 and was updated as recently as 8/1/2022. There are 9 different locations where 47 people can take part in the study."
Are numerous locations in America administering this test currently?
"There are 9 sites enrolling patients at the moment, with locations in Basking Ridge, Commack, Middletown and 6 other cities. If you're considering participating in this trial, pick a clinic near you to limit travel."
What are the most common side effects of Pembrolizumab?
"Pembrolizumab falls into the Phase 2 category, which means that while there is some evidence supporting its safety, none exists for efficacy. Our team at Power gave it a score of 2."
What are the primary cancers that pembrolizumab is approved to target?
"Pembrolizumab is an effective treatment for malignant neoplasms, unresectable melanoma, and microsatellite instability high."
Share this study with friends
Copy Link
Messenger